title: The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
authors: Masanori
authors: M
authors: Mori
authors: Julian
authors: J
authors: Sprague
mesh_terms: D059786:Abnormal Karyotype; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D020732:Cytogenetic Analysis; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D041905:Erythroid Cells / Q000473:pathology; D005260:Female; D020440:Gene Duplication; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D012074:Remission Induction; D000077157:Sorafenib; D020080:Tandem Repeat Sequences / Q000235:genetics / Q000502:physiology; D013997:Time Factors; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3